Search results
7 mar 2024 · Researchers at the University of North Carolina believe that if a suitably broad norovirus vaccine is administered to children who are around six months old, the jab could then guide the...
19 gru 2021 · While vaccines against norovirus diseases have been shown to be of high significance, the development of a broadly effective norovirus vaccine remains difficult, owing to the wide genetic and antigenic diversity of noroviruses with multiple co-circulated variants of various genotypes.
1 paź 2024 · Moderna, Inc. today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403.
1 dzień temu · Norovirus (NV) is a leading cause of acute gastroenteritis globally, yet no specific therapy currently exists for norovirus gastroenteritis (NVG). VXA-GI.1-NN is a nonreplicating adenovirus-vectored thermostable oral vaccine that has demonstrated safety and tolerability in clinical trials, generating robust serum and mucosal immune responses.
1 paź 2024 · The mRNA-LNP bivalent vaccine encoding the major capsid protein VP1 from GI.1 and GII.4 of human norovirus, generated high levels of neutralizing antibodies, robust cellular responses, and ...
29 maj 2024 · There is currently no licensed vaccine for norovirus AGE, and many features of the virus and the human immune response to it have made vaccine development a challenge.
Norovirus is a viral illness that is the most common cause of acute gastroenteritis globally. Symptoms of norovirus include acute onset diarrhea and vomiting. Emerging evidence suggest that norovirus infection is associated with intestinal inflammation, malnutrition and may cause long-term morbidity. (1)
